Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Experimental and clinical evidence supports the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinflammatory medication that is indicated for the treatment of gout and pericarditis. METHODS: We performed a randomized, double-blind trial involving patients recruited within 30 days after a myocardial infarction. The patients were randomly assigned to receive either low-dose colchicine (0.5 mg once daily) or placebo. The primary efficacy end point was a composite of death from cardiovascular causes, resuscitated cardiac arrest, myocardial infarction, stroke, or urgent hospitalization for angina leading to coronary revascularization. The components of the primary end point and safety were also assessed. RESULTS: A total of 4745 patients were enrolled; 2366 patients were assigned to the colchicine group, and 2379 to the placebo group. Patients were followed for a median of 22.6 months. The primary end point occurred in 5.5% of the patients in the colchicine group, as compared with 7.1% of those in the placebo group (hazard ratio, 0.77; 95% confidence interval [CI], 0.61 to 0.96; P = 0.02). The hazard ratios were 0.84 (95% CI, 0.46 to 1.52) for death from cardiovascular causes, 0.83 (95% CI, 0.25 to 2.73) for resuscitated cardiac arrest, 0.91 (95% CI, 0.68 to 1.21) for myocardial infarction, 0.26 (95% CI, 0.10 to 0.70) for stroke, and 0.50 (95% CI, 0.31 to 0.81) for urgent hospitalization for angina leading to coronary revascularization. Diarrhea was reported in 9.7% of the patients in the colchicine group and in 8.9% of those in the placebo group (P = 0.35). Pneumonia was reported as a serious adverse event in 0.9% of the patients in the colchicine group and in 0.4% of those in the placebo group (P = 0.03). CONCLUSIONS: Among patients with a recent myocardial infarction, colchicine at a dose of 0.5 mg daily led to a significantly lower risk of ischemic cardiovascular events than placebo. (Funded by the Government of Quebec and others; COLCOT ClinicalTrials.gov number, NCT02551094.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trials have shown that targeted inhibition of this inflammatory pathway, as measured by changes in CRP concentrations, can reduce the rate of cardiovascular events.5, 6, 7”
From Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials (2023) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This was also not an isolated finding as a similar reduction of CVD risk linked to reduction of inflammation was reported in the COLCOT trial when participants were given low‐dose colchicine (a standard anti‐inflammatory drug) (Tardif et al., 2019).”
From Treatment of periodontitis and C ‐reactive protein: A systematic review and meta‐analysis of randomized clinical trials (2023) · cites this paper as Tardif et al., 2019
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Reduction in LDL-C has been strongly associated with improved cardiovascular outcomes, and 3 recent trials have demonstrated favorable effects with anti-inflammatory therapies.[21][22][23][24]”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [23]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Reduction in LDL-C has been strongly associated with improved cardiovascular outcomes, and 3 recent trials have demonstrated favorable effects with anti-inflammatory therapies.[21][22][23][24]”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [23]
Experimental — accuracy not yet measuredIn the citing paper
“However, when appraised together, the evidence supports apolipoprotein B as being necessary for lipid-mediated atherogenesis by LDL-C to occur. 57,58 .”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [58]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
The Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain
Ravelli, R. B. G., Gigant, B., Curmi, P. A., Jourdain, I., Lachkar, S., Sobel, A., & Knossow, M. (2004) · Nature · doi:10.1038/nature02393 · Cited by 1,630
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
Ridker, P. M., Everett, B. M., Pradhan, A., MacFadyen, J. G., Solomon, D. H., Zaharris, E., Mam, V., Hasan, A., Rosenberg, Y., Iturriaga, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1809798 · Cited by 1,317
Self-citationLow-Dose Colchicine for Secondary Prevention of Cardiovascular Disease
Nidorf, S. M., Eikelboom, J. W., Budgeon, C. A., & Thompson, P. L. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.10.027 · Cited by 1,054
Semiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Imazio, M., Bobbio, M., Cecchi, E., Demarie, D., Demichelis, B., Pomari, F., Moratti, M., Gaschino, G., Giammaria, M., Ghisio, A., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.542738 · Cited by 614
Cited by
Items 701–800 of 1,006
Taqueti, V. R., Shah, A. M., Everett, B. M., Pradhan, A. D., Piazza, G., Bibbo, C. F., Hainer, J. M., Morgan, V., de Souza, A. C. D. A. H., Skali, H., et al. (2022) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2022.08.009 · Cited by 32
“Inflammation has emerged as a potential therapeutic target in the management of ischemic heart disease based on results from 3 large randomized, double-blind, placebo-controlled clinical trials.(3-5) CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) enrolled patients with a previous myocardial infarctio…”
BackgroundImpact of Impaired Cholesterol Homeostasis on Neutrophils in Atherosclerosis
Tucker, B., Ephraums, J., King, T. W., Abburi, K., Rye, K., & Cochran, B. J. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.316246 · Cited by 31
Cederström, S., Lundman, P., Alfredsson, J., Hagström, E., Ravn‐Fischer, A., Söderberg, S., Yndigegn, T., Tornvall, P., & Jernberg, T. (2023) · Scientific Reports · doi:10.1038/s41598-023-39051-3 · Cited by 36
Novel Anti-Inflammatory Therapies in Coronary Artery Disease and Acute Coronary Syndromes
Dimitroglou, Y., Aggeli, C., Theofilis, P., Tsioufis, P., Oikonomou, E. K., Chasikidis, C., Tsioufis, K. P., & Tousoulis, D. (2023) · Life · doi:10.3390/life13081669 · Cited by 40
“Regarding adverse effects, pneumonia was reported significantly more often in patients assigned to the colchicine group [70].”
BackgroundHigh-Risk Coronary Plaque Features: A Narrative Review
Dawson, L. P., & Layland, J. J. (2022) · Cardiology and Therapy · doi:10.1007/s40119-022-00271-9 · Cited by 34
“Several trials have demonstrated reduced CV events with colchicine treatment following ACS [92, 93], and further studies assessing the impact of colchicine on coronary plaque features are underway.”
BackgroundThe key role of inflammation in the pathogenesis and management of obesity and CVD
Boutari, C., Hill, M. A., Procaccini, C., Matarese, G., & Mantzoros, C. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155627 · Cited by 31
Du, M., Xu, L., Zhang, X., Huang, X., Cao, H., Qiu, F., Lan, W., & Jiang, H. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s419087 · Cited by 29
“Recently, several studies found that lowing systematic inflammation in the acute phase was associated with the improved tissue salvage and reduced risk of vascular events.(12,13) Systemic inflammation can be manifested by changes in the peripheral inflammatory parameters,”
BackgroundColchicine for cardiovascular prevention: the dawn of a new era has finally come
Bonaventura, A., & Abbate, A. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad453 · Cited by 31
Chen, M., Yang, D., Zhou, Y., Yang, C., Lin, W., Li, J., Liu, J., Ye, J., Huang, W., Ma, W., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.93544 · Cited by 34
“…subsequently identified to emerge as an effective therapeutic agent in cardiovascular diseases and was approved by the U.S. Food and Drug Administration to use in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease in June 2023 [14-17].”
Zhang, Y., Zhang, X., Shi, S.-R., Ma, C., Lin, Y.-P., Song, W.-G., & Guo, S. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1372055 · Cited by 49
Role of inflammation and evidence for the use of colchicine in patients with acute coronary syndrome
Bulnes, J. F., González, L., Velásquez, L., Paz, O. M., Venturelli, P. M., & Martínez, G. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1356023 · Cited by 31
Kelly, D., Kelleher, E. M., & Rothwell, P. M. (2025) · Stroke · doi:10.1161/strokeaha.124.047070 · Cited by 37
“107,108 COLCOT included 4745 patients within 30 days after myocardial infarction and showed a 23% reduction in the primary cardiovascular end point with colchicine versus placebo, while LoDoCo2 recruited 5522 patients who had stable CAD for at least 6 months and demonstrated a 31% risk reduction in…”
Muro, F. M. D., Vogel, B., Sartori, S., Bay, B., Oliva, A., Feng, Y., Krishnan, P., Sweeny, J. M., Gitto, M., Smith, K. F., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf112 · Cited by 36
Clonal haematopoiesis of indeterminate potential and mortality in coronary artery disease
von Scheidt, M., Adkar, S. S., Krefting, J., Hoermann, G., Meggendorfer, M., Bauer, S., Mitchell, S. R., Pugach, I., Frieß, C., Ma, A., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf602 · Cited by 49
Colchicine Use and Incident Coronary Artery Disease in Male Patients With Gout
Shah, B., Toprover, M., Crittenden, D. B., Jeurling, S., Pike, V. C., Krasnokutsky, S., Xia, Y., Fisher, M. C., Slobodnick, A., Tenner, C. T., et al. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.05.026 · Cited by 30
Considering Cause and Effect of Immune Cell Aging on Cardiac Repair after Myocardial Infarction
Tobin, S. W., Alibhai, F. J., Weisel, R. D., & Li, R. (2020) · Cells · doi:10.3390/cells9081894 · Cited by 35
Wu, S., Yang, Y., Zhu, J., Ren, J., Wang, J., Zhang, H., & Shao, X. (2021) · Angiology · doi:10.1177/00033197211000495 · Cited by 30
Regulatory T Cell-Enhancing Therapies to Treat Atherosclerosis
Ait‐Oufella, H., Lavillegrand, J., & Tedgui, A. (2021) · Cells · doi:10.3390/cells10040723 · Cited by 31
“Yet recent clinical trials highlighting the clinical benefit of inflammationtargeted therapy with anti-interleukin (IL)-1β neutralizing antibodies [1] or colchicine [2,3] for the prevention of recurrent events in patients recovering from an acute coronary syndrome (ACS), or in the stable phase of coronary artery disea…”
BackgroundUlander, L., Tolppanen, H., Hartman, O., Rissanen, T. T., Paakkanen, R., Kuusisto, J. K., Anttonen, O. M., Nieminen, T. V. M., Yrjölä, J., Ryysy, R., et al. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.04.062 · Cited by 30
Pan, G., Chang, L., Zhang, J., Liu, Y., Hu, L., Zhang, S., Zhang, J., Qiao, J., Jakopin, Ž., Hu, H., et al. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114315 · Cited by 32
NETosis in ischemic/reperfusion injuries: An organ-based review
Hashemi, P., Nouri‐Vaskeh, M., Alizadeh, L., Baghbanzadeh, A., Badalzadeh, R., Askari, E., & Baradaran, B. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120158 · Cited by 31
Bönner, F., Gastl, M., Nienhaus, F., Rothe, M., Jahn, A., Pfeiler, S., Gross, U., Schultheiss, H.-P., Ibáñez, B., Kozerke, S., et al. (2022) · Basic Research in Cardiology · doi:10.1007/s00395-022-00928-5 · Cited by 29
“reduce patient morbidity and mortality [12, 38].”
Singh, D., Rai, V., & Agrawal, D. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213731 · Cited by 31
Advances in immunotherapy modalities for atherosclerosis
Meng, Q., Liu, H., Liu, J., Pang, Y., & Liu, Q. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1079185 · Cited by 32
“The COLCOT trial demonstrated for the first time the cardiovascular benefits of colchicine’s anti-inflammatory effects, reducing the risk of major cardiovascular events in patients after myocardial infarction by 23% (Tardif et al., 2019).”
BackgroundLi, Z., Lin, C., Cai, X., Hu, S., Lv, F., Yang, W., Zhu, X., & Ji, L. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.06.972 · Cited by 33
Temporal Trends in Noncardiovascular Morbidity and Mortality Following Acute Myocardial Infarction
Christensen, D. M., Strange, J. E., El-Chouli, M. H., Falkentoft, A. C., Malmborg, M. W., Nouhravesh, N., Gislason, G., Schou, M., Torp-Pedersen, C. T., & Sehested, T. S. G. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.06.024 · Cited by 31
Shi, J., Yang, M. M., Yang, S., Fan, F., Zheng, G., Miao, Y., Hua, Y., Zhang, J., Cheng, Y., Liu, S., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155489 · Cited by 32
The role of the NLRP3 inflammasome in atherosclerotic disease: Systematic review and meta-analysis
Khair, M., Khair, M., Vangaveti, V., & Malabu, U. H. (2024) · Journal of Cardiology · doi:10.1016/j.jjcc.2024.03.003 · Cited by 36
Bosco, G., Barbagallo, F. D. G., Marco, M. D., Scilletta, S., Miano, N., Capuccio, S., Musmeci, M., Mauro, S. D., Filippello, A., Scamporrino, A., et al. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.12.002 · Cited by 29
Araujo, G., Valencia, L. M., Martin-Ozimek, A., Soto, Y., & Proctor, S. D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1485801 · Cited by 34
A Perspective on Targeting Inflammation and Cytokine Actions in Atherosclerosis
Chan, Y., & Ramji, D. P. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0301 · Cited by 31
“In a small patient subgroup (where data were available), CRP was reduced by over 65% in the first 6 months post-MI with similar changes in leukocyte counts observed in both groups (although not significant) [61].”
InfluentialNovel Positron Emission Tomography Tracers for Imaging Vascular Inflammation
Ćorović, A., Wall, C., Mason, J. C., Rudd, J. H. F., & Tarkin, J. M. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01372-4 · Cited by 28
Inflammation as a determinant of healing response after coronary stent implantation
Ochijewicz, D., Tomaniak, M., Opolski, G., & Kochman, J. (2021) · International journal of cardiac imaging · doi:10.1007/s10554-020-02073-3 · Cited by 40
“In patients within 30 days after myocardial infarction and in patients with chronic coronary syndrome administration of colchicine significantly decreased ischemic cardiovascular events in comparison to placebo [87, 88].”
BackgroundBenz, A. P., Aeschbacher, S., Krisai, P., Moschovitis, G., Blum, S., Meyre, P. B., Blum, M. R., Rodondi, N., Valentino, M. D., Kobza, R., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019168 · Cited by 33
Ma, J., Liu, X., Qiao, L., Meng, L., Xu, X., Xue, F., Cheng, C., Han, Z., Lu, Y., Zhang, W., et al. (2021) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.121.010764 · Cited by 29
Comprehensive Assessment of High-Risk Plaques by Dual-Modal Imaging Catheter in Coronary Artery
Kim, S., Nam, H. S., Lee, M. W., Kim, H. J., Kang, W. J., Song, J. W., Han, J., Kang, D. O., Oh, W., Yoo, H., et al. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.10.005 · Cited by 30
“Recent trials have provided convincing evidence that the interventions targeting residual inflammatory burden could further reduce the cardiovascular risk (42,43).”
BackgroundDolu, A. K., Karayiğit, O., Özkan, C., Çelik, M. C., & Kalçık, M. (2022) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2022.2035082 · Cited by 33
Risk of cardiovascular events in patients having had acute calcium pyrophosphate crystal arthritis
Tedeschi, S. K., Huang, W., Yoshida, K., & Solomon, D. H. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2022-222387 · Cited by 30
Formulation and Evaluation of a Drug-in-Adhesive Patch for Transdermal Delivery of Colchicine
Lei, Y., Yang, G., Du, F., Yi, J., Quan, L., Liu, H., Zhou, X., Gong, W., Han, J., Wang, Y., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102245 · Cited by 31
Cholesterol trafficking, lysosomal function, and atherosclerosis
Skeyni, A., Pradignac, A., Matz, R. L., Terrand, J., & Boucher, P. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00415.2023 · Cited by 33
Ea, H., Kischkel, B., Chirayath, T. W., Klück, V., Aparicio, C., Loeung, H. U., Manivet, P., Jansen, T., Zarka, M., Lioté, F., et al. (2024) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2023-225305 · Cited by 29
The sooner, the better: anti-inflammation in acute myocardial infarction
Lüscher, T. F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa752 · Cited by 35
“5 mg daily and were followed-up for a median of 2 years.(20) Impressively, colchicine led to a 23% reduction of”
BackgroundInhibiting Interleukin-6 to Reduce Cardiovascular Event Rates
Ridker, P. M. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.060 · Cited by 28
Figueiredo, C. S., Roseira, E. S., Viana, T. T., Silveira, M. A. D., de Melo, R. M. V., Fernandez, M. G., Lemos, L. M. G., & Passos, L. C. S. (2023) · Pharmaceuticals · doi:10.3390/ph16091242 · Cited by 35
“[18] 2019 4745 Patients who had AMI within 30 days and were treated with PCI and were using statins and OMT Colchicine 0.”
Nazari, I. S., & Feinstein, M. J. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00098-22 · Cited by 31
“…the Colchicine Cardiovascular Outcomes Trial (COLCOT) and the second low-dose colchicine trial (LODOCO2) found that 0.5 mg of colchicine daily significantly decreased the risk of cardiovascular events in patients with recent MI and patients with chronic coronary disease, respectively (195, 196).”
BackgroundInfluentialKhan, D., Zhou, H., You, J., Kaiser, V. A., Khajuria, R. K., & Muhammad, S. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01594-x · Cited by 31
“Clinical trials and experimental animal studies reported the beneficial effects of colchicine against CVDs [22, 23, 25, 28, 29].”
BackgroundRecent Advances in Immunothrombosis and Thromboinflammation
Kaiser, R. W. J., Gold, C., & Stark, K. (2025) · Thrombosis and Haemostasis · doi:10.1055/a-2523-1821 · Cited by 37
Shabbir, A., Rathod, K. S., Khambata, R. S., & Ahluwalia, A. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023229 · Cited by 30
Whelton, S. P., Berning, P., Blumenthal, R. S., Marshall, C. H., Martin, S. S., Mortensen, M. B., Blaha, M. J., & Dzaye, O. D. A. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.02.003 · Cited by 30
Anti-inflammatory Therapies for Coronary Heart Disease: A Systematic Review and Meta-Analysis
Wang, H., Jiang, M., Li, X., Zhao, Y., Shao, J., Liu, Z., Lin, L., Xu, Q., Wang, L., Lu, X.-C., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.726341 · Cited by 33
“Four eligible RCTs compared colchicine with placebo (9, 14, 15, 18, 26).”
BackgroundLi, J., Zhang, X., Yang, M., Yang, H., Xu, N., Fan, X., Liu, G., Jiang, X., Fan, J., Zhang, L., et al. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01152-z · Cited by 28
“Recently, COLCOT (Colchicine Cardiovascular Outcomes Trial) showed colchicine led to a substantially lower risk of ischemic cardiovascular events in patients with a proinflammatory constitution [34].”
BackgroundRole of extracellular vesicles in atherosclerosis: An update
Coly, P., & Boulanger, C. M. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mir0221-099r · Cited by 32
Komatsu, S., Yutani, C., Takahashi, S., Takewa, M., Ohara, T., Hirayama, A., & Kodama, K. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.03.010 · Cited by 27
Niu, Y., Bai, N., Ma, Y., Zhong, P.-Y., Shang, Y.-S., & Wang, Z.-L. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02525-9 · Cited by 29
Tackling inflammation in atherosclerosis: Are we there yet and what lies beyond?
Bhattacharya, P., Kanagasooriyan, R., & Subramanian, M. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102283 · Cited by 33
Klapproth, E., Witt, A., Klose, P., Wiedemann, J., Vavilthota, N., Künzel, S. R., Kämmerer, S., Günscht, M., Sprott, D., Lesche, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35331-0 · Cited by 27
Chronic rheumatologic disorders and cardiovascular disease risk in women
Mehta, P. K., Levit, R. D., Wood, M. J., Aggarwal, N. R., O’Donoghue, M. L., Lim, S. S., Lindley, K., Gaignard, S. M., Quesada, O., Vatsa, N., et al. (2023) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2023.100267 · Cited by 39
“In the Colchicine Cardiovascular Outcomes Trial (COLCOT), this agent was effective in preventing major adverse cardiac events in patients with recent myocardial infarction [92].”
BackgroundIL-6 in pulmonary hypertension: why novel is not always best
Toshner, M. R., & Rothman, A. M. K. (2020) · European Respiratory Journal · doi:10.1183/13993003.00314-2020 · Cited by 27
Colchicine for Secondary Cardiovascular Prevention in Coronary Disease
Roubille, F., & Tardif, J. (2020) · Circulation · doi:10.1161/circulationaha.120.051240 · Cited by 29
Self-citationLeukocyte–endothelial interaction in CKD
Sarakpi, T., Mesic, A., & Speer, T. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad135 · Cited by 30
“Both the Colchicine Cardiovascular Outcomes Trial (COLCOT) trial [174] and the LoDoCo2 (Low-Cose Colchicine 2) trial [175] showed beneficial effects in CVD prevention after myocardial infarction or in patients with stable CAD, respectively.”
BackgroundMatsushita, K., Marchandot, B., Trimaille, A., Hmadeh, S., Kibler, M., Heger, J., Carmona, A., Hess, S., Reydel, A., Jesel, L., et al. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14435 · Cited by 28
“Colchicine is another anti-inflammatory drug that targets microtubule function,(123) and its cardioprotective effects have been evidenced in patients with ischaemic heart disease.(124) The ef-”
BackgroundAtherosclerosis antigens as targets for immunotherapy
Raposo-Gutiérrez, I., Rodríguez-Ronchel, A., & Ramiro, A. R. (2023) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00376-x · Cited by 27
“The IgH and IgL chains include a variable region at anti-inflammatory treatment with colchicine led to a significantly lower risk of ischemic cardiovascular events among patients with a recent myocardial infarction 14,15 .”
BackgroundHypercholesterolemia and inflammation—Cooperative cardiovascular risk factors
Gallo, A., Goff, W. L., Santos, R. D., Fichtner, I., Carugo, S., Corsini, A., Sirtori, C. R., & Ruscica, M. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14326 · Cited by 33
Wang, L., Yu, C., You, T., Zhang, X., Su, H., Cao, B., Anwaier, S., Xiang, H., Dai, C., Long, X., et al. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.12.013 · Cited by 37
“Consequently, immediate therapeutic measures through modulation of the post-myocardial infarction inflammatory response may confer substantial advantages to patients with myocardial infarction [31].”
The Role of NLRP3 Inflammasome in Type 2 Diabetes Mellitus and Its Macrovascular Complications
Karamitsos, K., Oikonomou, E. K., Theofilis, P., Ikonomidis, I., Kassi, E. N., Lambadiari, V., GIALAFOS, E. J., Tsatsaragkou, A., Mystakidi, V. C., Zisimos, K., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134606 · Cited by 38
“In murine myocardial infarction models, colchicine reduced inflammation and preserved cardiac function [81].”
Kurt, B., Rex, K., Reugels, M., Fordyce, C. B., Fudim, M., Sharma, A., Berger, M., Marx, N., Marx-Schütt, K., & Kahles, F. (2025) · Current Heart Failure Reports · doi:10.1007/s11897-025-00710-3 · Cited by 36
Inflammatory Mechanisms in Acute Coronary Syndromes: From Pathophysiology to Therapeutic Targets
Brie, D. M., Mornoş, C., Adam, O., Tîrziu, A., Popescu, R., & Brie, A. D. (2025) · Cells · doi:10.3390/cells15010072 · Cited by 34
“No significant differences were observed between groups in cardiovascular mortality or recurrent MI (HR = 0.77 (95% CI: 0.61–0.96), p = 0.02 reduction in the risk of major cardiovascular events) [182].”
InfluentialBeyond Self-Recycling: Cell-Specific Role of Autophagy in Atherosclerosis
Henderson, J. M., Weber, C., & Santovito, D. (2021) · Cells · doi:10.3390/cells10030625 · Cited by 30
Single cell analyses to understand the immune continuum in atherosclerosis
Hill, C. A., Fernandez, D. M., & Giannarelli, C. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.04.003 · Cited by 28
Seong, E., Lee, J., Lim, S., Park, E., Kim, E., Kim, C. W., Lee, E. M., Oh, G. C., Choo, E. H., Hwang, B., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020502 · Cited by 25
Montarello, N. J., Singh, K., Sinhal, A. R., Wong, D. T. L., Alcock, R. F., Rajendran, S., Dautov, R. F., Barlis, P., Patel, S., Nidorf, S. M., et al. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07240-9 · Cited by 28
Inflammation and Heart Failure: Searching for the Enemy—Reaching the Entelechy
PARASKEVAIDIS, I. A., Farmakis, D. T., Papingiotis, G., & Tsougos, E. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10010019 · Cited by 28
“The Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) and the Colchicine Cardiovascular Outcomes Trial (COLCOT) were the first two randomized clinical trials that showed promising results in the prevention of cardiovascular medicine [6,7].”
Dimosiari, A., Patoulias, D., Kitas, G. D., & Dimitroulas, T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041302 · Cited by 29
“The only “anti-inflammatory” treatment that has been shown to provide significant cardiovascular benefits, mainly in the field of secondary prevention of CVD, is colchicine [80,81], while others, such as low-dose methotrexate, have completely failed in this direction [82].”
BackgroundKumrić, M., Urlić, H., Božić, J., Vilović, M., Kurir, T. T., Glavaš, D., Miric, D., Zanchi, J., Bradarić, A., Lozo, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098062 · Cited by 28
“On the other hand, colchicine, a well-established medication in terms of treating gout and pericarditis, was explored in the Colchicine Cardiovascular Outcomes Trial (COLCOT) [118].”
BackgroundThe effect of immunomodulatory drugs on aortic stenosis: a Mendelian randomisation analysis
Ciofani, J. L., Han, D., Nazarzadeh, M., Allahwala, U. K., Maria, G. L. D., BANNING, A. P., Bhindi, R., & Rahimi, K. (2023) · Scientific Reports · doi:10.1038/s41598-023-44387-x · Cited by 27
“…rates of further cardiovascular events in patients treated with colchicine compared to placebo, and the Low-Dose Colchicine trial in 5522 patients with chronic coronary disease similarly demonstrated reduced cardiovascular event rates in patients treated with colchicine compared to placebo 18,19 .”
BackgroundMethodThe Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease
Roman, Y. M., Hernández, A. V., & White, C. M. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020922994 · Cited by 29
Inflammation-Related Risk Loci in Genome-Wide Association Studies of Coronary Artery Disease
Mauersberger, C., Schunkert, H., & Sager, H. B. (2021) · Cells · doi:10.3390/cells10020440 · Cited by 30
“Soon thereafter, low dose colchicine, another drug with anti-inflammatory properties, showed a promising effect in patients after myocardial infarction and recently also in patients with chronic coronary syndrome [2,3].”
BackgroundImmunomodulation of Myocardial Fibrosis
Sikking, M. A., Stroeks, S. L. V. M., Marelli‐Berg, F. M., Heymans, S. R. B., Ludewig, B., & Verdonschot, J. A. J. (2023) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.03.015 · Cited by 31
Targeting Neutrophil Extracellular Traps for Stroke Prognosis: A Promising Path
Liaptsi, E., Merkouris, E., Polatidou, E., Tsiptsios, D., Gkantzios, A., Kokkotis, C., Petridis, F., Christidi, F., Karatzetzou, S., Karaoglanis, C., et al. (2023) · Neurology International · doi:10.3390/neurolint15040076 · Cited by 31
“Intriguingly, the authors commented that recruited patients receiving colchicine were less likely to present with a stroke or to be urgently hospitalized for angina [50].”
Robinson, K. A., Akbar, N., Baidžajevas, K., & Choudhury, R. P. (2023) · The FASEB Journal · doi:10.1096/fj.202301078r · Cited by 29
“In addition to drugs that target inflammatory cytokines, drugs that inhibit the NLRP3 inflammasome such as colchicine led to a significantly lower risk of cardiovascular events in patients with recent myocardial infarction 80 (COLCOT) or chronic coronary disease 81 (Lo-DoCo2).”
BackgroundJansen, S. J., de Borst, G. J., Hinchliffe, R. J., & Teraa, M. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.09.021 · Cited by 30
Mulholland, M., Depuydt, M. A. C., Jakobsson, G., Ljungcrantz, I., Grentzmann, A., To, F., Bengtsson, E., Gyllenbäck, E. J., Grönberg, C., Rattik, S., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae046 · Cited by 27
“33 Treatment with colchicine in patients who experienced a recent myocardial infarction (COLCOT trial) 34 or patients with chronic coronary disease (LoDoCo2 trial) 35 led to a decrease in adverse cardiovascular events compared with placebo controls.”
BackgroundTsiachristas, A., Chan, K., Wahome, E., Kearns, B., Patel, P., Lyasheva, M., Syed, N., Fry, S., Halborg, T., West, H. W., et al. (2024) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcae085 · Cited by 38
Self-citationPedretti, R. F. E., Asteggiano, R., Gevaert, A. B., Bowen, T. S., Caselli, S., Cornelissen, V., Christodorescu, R., Derosa, G., Diévart, F., Kurpas, D., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf175 · Cited by 41
Wang, L., Zhang, Y., & Zhang, S. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00078 · Cited by 28
Toprover, M., Shah, B., Oh, C., Igel, T. F., Romero, A. G., Pike, V. C., Curovic, F., Bang, D., Lazaro, D. M., Krasnokutsky, S., et al. (2020) · Arthritis Research & Therapy · doi:10.1186/s13075-020-02260-6 · Cited by 26
Colchicine inhibits the prothrombotic effects of oxLDL in human endothelial cells
Cimmino, G., Conte, S., Morello, A., Pellegrino, G., Marra, L., Calı̀, G., Golino, P., & Cirillo, P. L. (2020) · Vascular Pharmacology · doi:10.1016/j.vph.2020.106822 · Cited by 25
Update on the Inflammatory Hypothesis of Coronary Artery Disease
Boland, J. L., & Long, C. S. (2021) · Current Cardiology Reports · doi:10.1007/s11886-020-01439-2 · Cited by 27
Canakinumab for Secondary Prevention of Coronary Artery Disease
Ortega‐Paz, L., Capodanno, D., & Angiolillo, D. J. (2021) · Future Cardiology · doi:10.2217/fca-2020-0211 · Cited by 29
The Use of Colchicine in Cardiovascular Diseases: A Systematic Review
Siak, J., Flint, N., Shmueli, H., Siegel, R. J., & Rader, F. (2021) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.01.019 · Cited by 27
Managing dyslipidemia in patients with Type 2 diabetes
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1912734 · Cited by 33
“intensive statin treatment, anti-inflammatory treatment such as low-dose colchicine might be considered [154,155],”
BackgroundWeber, B., Biery, D. W., Singh, A., Divakaran, S., Berman, A. N., Wu, W. Y., Brown, J. M., Hainer, J. M., Nasir, K., Liao, K. P., et al. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa154 · Cited by 27
“recent data in the general population from the Colchicine Cardiovascular Outcomes Trial (COLCOT) suggests that reducing inflammation with colchicine in the post-MI period reduces rates of major CV events.(29) Despite the enhanced CV risk associated with systemic inflammatory disorders, it is known that the 10-year ASC…”
ResultDurstenfeld, M. S., & Hsue, P. Y. (2021) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000681 · Cited by 27
Diaz‐Arocutipa, C., Benites‐Meza, J. K., Chambergo‐Michilot, D., Barboza, J. J., Pasupuleti, V., Bueno, H., Sambola, A., & Hernández, A. V. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.676771 · Cited by 29
“(21) found an increase in pneumonia cases in the colchicine group in comparison to placebo (0.”
BackgroundMethodResultInfluentialDagher, O., Mury, P., Noly, P., Fortier, A., Lettre, G., Thorin, É., & Carrier, M. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.741542 · Cited by 30
“Recently, three large-scale randomized controlled trials, CANTOS (6), CIRT (7), and COLCOT (8), explored these benefits in the context of an ACS.”
BackgroundMannarino, M. R., Bianconi, V., Gigante, B., Strawbridge, R. J., Savonen, K. P., Kurl, S., Giral, P., Smit, A. J., Eriksson, P. O., Tremoli, E., et al. (2021) · BioFactors · doi:10.1002/biof.1801 · Cited by 28
Inflammatory Burden and Immunomodulative Therapeutics of Cardiovascular Diseases
Kao, T., & Huang, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020804 · Cited by 23
“In the Colchicine Cardiovascular Outcomes trials (COLCOT) [39] study with 4745 participants sustaining recent MI within one month, the introduction of low-dose colchicine was associated with a significant reduction in subsequent ischaemic cardiovascular events.”
BackgroundImmunity, Vascular Aging and Stroke
Louka, A. M., Sagris, D., & Ntaios, G. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220103101700 · Cited by 28
Lin, Y., Yeh, C., Kuo, K.-T., Fong, I.-H., Yadav, V. K., Kounis, N. G., Hu, P., & Hung, M. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/9964689 · Cited by 31
Platelets, Thromboinflammation and Neurovascular Disease
Sun, Y., & Langer, H. F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.843404 · Cited by 31
Metadata
- Authors
- Tardif, J.-C., Kouz, S., Waters, D. D., Bertrand, O. F., Diaz, R., Maggioni, A. P., Pinto, F. J., Ibrahim, R., Gamra, H., Kiwan, G. S., Berry, C., López-Sendón, J., Ostadal, P., Koenig, W., Angoulvant, D., Grégoire, J. C., Lavoie, M.-A., Dubé, M.-P., Rhainds, D., Provencher, M., Blondeau, L., Orfanos, A., L’Allier, P. L., Guertin, M.-C., & Roubille, F.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- From the Montreal Heart Institute (J.-C.T., R.I., J.C.G., M.-A.L., M.-P.D., D.R., P.L.L.) and the Montreal Health Innovations Coordinating Center (M.P., L.B., A.O., M.-C.G.), Montreal, Centre Hospitalier Régional de Lanaudière, Joliette (S.K.), and Institut de Cardiologie et Pneumologie de Québec, Quebec City (O.F.B.) — all in Canada; San Francisco General Hospital, San Francisco (D.D.W.); Estudios Clínicos Latinoamérica, Rosario, Argentina (R.D.); Associazione Nazionale Medici Cardiologi...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-12-26
- Volume
- 381
- Issue
- 26
- Pages
- 2497-2505
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2986700515
- Cited by
- 3,159
- References
- 20
- Citations by year
- 2026: 505 · 2025: 519 · 2024: 445 · 2023: 415 · 2022: 414 · 2021: 485 · 2020: 361 · 2019: 10
- FWCI
- 230.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- HAL (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion)
- Funders
- Government of Quebec
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- colchicine, myocardial infarction, anti-inflammatory therapy, inflammation in atherosclerosis, cardiovascular mortality, major adverse cardiovascular events, stroke, angina pectoris, diarrhea, pneumonia, drug safety, low-dose colchicine, secondary prevention, coronary revascularization, cardiac arrest, myocardial infarction recurrence, cardiovascular risk reduction, cost-effectiveness, quality of life
- MeSH terms
- Aged, Angina Pectoris, Anti-Inflammatory Agents, C-Reactive Protein, Cardiovascular Diseases, Colchicine, Double-Blind Method, Female, Humans, Male, Middle Aged, Myocardial Infarction, Recurrence, Biomarkers, Incidence, Proportional Hazards Models, Stroke, Kaplan-Meier Estimate, Intention to Treat Analysis, Percutaneous Coronary Intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

